Case Report: Semaglutide-associated depression: a report of two cases
Source : https://www.frontiersin.org/articles/10.3389/fpsyt.2023.1238353/full
Semaglutide, as a glucagon-like peptide-1 receptor agonist (GLP-1 RA), was approved for glucose control in type 2 diabetes mellitus in 2017 and approved for weight loss in 2021 by the...
Conclusions/Relevance: Depression was improved or relieved after discontinuation of semaglutide in both cases. Possible psychiatric adverse effects of depression should be taken into consideration when semaglutide is administered to patients.
Share
Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review
Source : https://www.frontiersin.org/articles/10.3389/fendo.2023.1244432/full
PurposeThis study aimed to perform a network meta-analysis to objectively evaluate the efficacy and safety of 10 Glucagon-like peptide-1 receptor agonists (GLP-1RAs) in combination with metformin that is approved for...
Conclusion: This study’s results showed that GLP-1RAs were effective in lowering HbA1c and reducing body weight without increased incidence of hypoglycemic reactions. In addition, this study may provide reference and evidence-based medical evidence for clinicians to select GLP-1RAs in patients with T2D and high body mass index (BMI). Based...
Share
Knowledge and Attitude of the General Population in Saudi Arabia Toward Weight Management Medications (WMMs): A Cross-Sectional Study
Background: Over the past decades, the global prevalence of obesity has tripled, with the Kingdom of Saudi Arabia experiencing a notably higher rate of increase. While lifestyle modifications remain the...
Conclusion: This study reveals a limited knowledge and cautious attitude regarding WMMs in the Saudi population, despite the high prevalence of obesity. With prior use of WMMs correlating with better knowledge and more favorable attitudes, these findings emphasize the need for targeted interventions to enhance public awareness and safe usage...
Share
Conclusions/Relevance: Novo Nordisk, the drug’s manufacturer, also recently announced topline results from a trial investigating semaglutide’s effects on cardiovascular outcomes. The drug alongside standard of care treatment reduced major adverse cardiovascular events by 20% in the study, which involved 17 604 adult participants with...
Share
Conclusions/Relevance: The first study addressed specifically a high-risk population with diabetes and, the second, low or intermediary-risk individuals without diabetes. Tirzepatide, a novel dual GIP/GLP-1 agonist, although not yet tested in specific cardiovascular outcomes trials, could be an alternative since it induces loss in weight...
Share